Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Trading 0.2% Higher – Here’s Why

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)’s share price shot up 0.2% on Thursday . The company traded as high as $84.66 and last traded at $84.64. Approximately 4,804 shares traded hands during mid-day trading, a decline of 27% from the average daily volume of 6,590 shares. The stock had previously closed at $84.44.

Invesco Biotechnology & Genome ETF Stock Up 0.2%

The stock has a fifty day moving average of $81.96 and a two-hundred day moving average of $81.33. The stock has a market cap of $263.23 million, a price-to-earnings ratio of 20.44 and a beta of 0.72.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of large investors have recently made changes to their positions in the stock. Colonial Trust Advisors acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the fourth quarter valued at about $25,000. Comerica Bank grew its position in Invesco Biotechnology & Genome ETF by 86.2% during the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after buying an additional 175 shares during the period. Fifth Third Bancorp acquired a new position in Invesco Biotechnology & Genome ETF during the first quarter worth about $30,000. PNC Financial Services Group Inc. increased its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after buying an additional 245 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the third quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after buying an additional 342 shares in the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.